- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Orchid Pharma's annual results for FY25 show robust growth, with operating revenue at Rs. 921.93 Cr and profit after tax reaching Rs. 106.48 Cr, up from Rs. 819.37 Cr and Rs. 94.75 Cr in FY24, respectively. EPS stood at Rs. 20.99. The company also announced its 32nd AGM on September 20, 2025, where members will vote on reallocating QIP funds, significantly increasing investment in the Jammu manufacturing facility to Rs. 150 Cr, and approving substantial raw material purchases from Otsuka Chemicals. Key operational updates include acquiring global rights to its novel antibiotic, Enmetazobactam, and a positive USFDA inspection.